Substituted Piperazine Derivative Crystals A–I for Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystalline forms of the piperazine derivative (S)-4-(trifluoromethyl)-5-((1-((5-(5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one exhibit poor stability, solubility, and processing issues, which hinder their use in pharmaceutical applications.
Innovation Solution
Development of crystalline forms A to I of the piperazine derivative, characterized by specific X-ray diffraction peaks and prepared using solvents such as acetonitrile, ethanol, n-propanol, acetone, and their mixtures, enhancing stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous drug products are used, then ease of manufacture is improved, but product stability deteriorates due to poor chemical and physical stability
Solution Approach 1:
The patent applies phase transition by converting the amorphous phase to crystalline phase. The invention provides multiple crystalline forms (Forms A-I) with distinct X-ray diffraction patterns, transforming the unstable amorphous drug substance into stable crystalline structures. This phase transition resolves the contradiction by maintaining ease of manufacture through crystallization processes while dramatically improving chemical and physical stability of the pharmaceutical product.
2Ease of manufacture
If amorphous drug products are used, then ease of manufacture is improved, but processing difficulty increases due to poor filtration and agglomeration
Solution Approach 1:
The patent utilizes phase transition from amorphous to crystalline state to improve processing characteristics. The crystalline forms exhibit defined particle morphology and reduced tendency for agglomeration, enabling efficient filtration and processing operations while maintaining manufacturing feasibility through established crystallization methodologies.
3Ease of manufacture
If amorphous drug products are used, then ease of manufacture is improved, but fluidity deteriorates due to poor flow properties
Solution Approach 1:
The patent applies phase transition to convert amorphous material with poor flow properties into crystalline forms with improved fluidity. The crystalline structures possess defined particle shapes and reduced interparticle adhesion, enhancing flow characteristics for downstream processing while maintaining ease of manufacture through controlled crystallization.
4Stability of the object's composition
If existing crystalline forms are used, then product stability is improved, but solubility deteriorates
Solution Approach 1:
The patent applies parameter changes by developing multiple crystalline polymorphs (Forms A-I) with different crystal packing arrangements, lattice energies, and surface properties. Each crystalline form exhibits distinct solubility characteristics while maintaining chemical stability. This allows selection of optimal crystalline forms that balance stability requirements with enhanced solubility for specific pharmaceutical applications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit improved chemical and physical stability, ease of processing, and enhanced oral bioavailability, facilitating the preparation of stable pharmaceutical dosage forms.
Implementation Method 1
Development of crystalline forms A to I of the piperazine derivative, characterized by specific X-ray diffraction peaks and prepared using solvents such as acetonitrile, ethanol, n-propanol, acetone, and their mixtures
Data Source
AI summary
Provided are a crystal of substituted piperazine derivative and a preparation method therefor. Specifically, provided are crystalline forms A to I of a compound represented by formula (1) and a preparation method therefor.